

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026.

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Come visit Rockwell Medical in Booth #1049 at ASN Kidney Week 2026 at the Colorado Convention Center in Denver, CO.

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--This marks the 3rd consecutive year that Rockwell Medical earned this recognition—climbing the ranks from #50 (2024) and #40 (2025) to #16 (2026).

Embecta (NASDAQ: EMBC - Get Free Report) and Rockwell Medical (NASDAQ: RMTI - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability. Profitability This table compares Embecta and Rockwell Medical's

Rockwell Medical, Inc. (RMTI) Q2 2026 Earnings Call Transcript

Rockwell Medical (RMTI) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.5 per share a year ago.

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodial

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical announces Q2'26 results, delivering strong year-over-year growth, expanding gross margin and generating positive operating cash flow.